Literature Scan

Literature Scan

New and noteworthy research from the medial literature landscape

Identifying Genetic Mutations That Can Predict Transplant Outcome in Patients With Myelodysplastic Syndromes

Tuesday, March 28th, 2017
Though allogeneic hematopoietic cell transplantation (alloHCT) is the only curative option for myelodysplastic syndromes (MDS), transplant-related mortality, complication rates, and available, suitable donors preclude...

Efficacy of Eltrombopag in Patients With Lower-Risk Myelodysplastic Syndromes and Thrombocytopenia

Tuesday, March 28th, 2017
Platelet transfusions are commonly administered to patients with myelodysplastic syndromes (MDS) who develop profound thrombocytopenia, but the short therapeutic effect and eventual transfusion refractoriness...

POT-KAST and POT-CAST: Questioning Routine Thromboprophylaxis After Casting or Knee Surgery

Tuesday, March 28th, 2017
The value of prescribing thromboprophylaxis to prevent venous thromboembolism (VTE) after knee arthroscopy or casting of the lower leg is debatable, and the risk−benefit...

Lenalidomide Maintenance Therapy Related to More Secondary Primary Malignancies in Older Adults

Wednesday, March 1st, 2017
Results from the Myeloma XI trial presented at the 2016 ASH Annual Meeting supported the use of lenalidomide as maintenance therapy for patients with...

Investigating Clonal Dynamics of Different Mutations in Myelodysplastic Syndromes

Wednesday, March 1st, 2017
In a whole-exome sequencing (WES) and targeted deep sequencing study published in Nature Genetics, researchers identified several biomarkers that could improve diagnosis and therapy...

TP53 Mutation Status Predicts Response to Decitabine for Patients With Acute Myeloid Leukemia...

Wednesday, March 1st, 2017
Patients with myelodysplastic syndromes (MDS) or acute myeloid leukemia (AML) who have unfavorable-risk cytogenetic abnormalities and TP53 mutations responded to treatment with decitabine, according...

Severe Fatigue Affects Survival and Social Reintegration for Hodgkin Lymphoma Survivors

Thursday, February 2nd, 2017
Approximately 40 percent of patients with Hodgkin lymphoma (HL) experience persistent fatigue, a chronic symptom that can affect patients years after successful treatment. In...

Is It Safe to Eliminate CHOP Consolidation Therapy for Patients With CD20+ Post-Transplant Lymphoproliferative...

Thursday, February 2nd, 2017
Results from the phase II PTLD-1 (Sequential Treatment of CD20-Positive Post-Transplant Lymphoproliferative Disorder) trial established sequential treatment with four cycles of weekly rituximab followed...

Enoxaparin Does Not Prevent Placenta-Mediated Complications in Pregnant Women With Severe Preeclampsia

Sunday, January 15th, 2017
Pregnant women who have severe preeclampsia (a disease characterized by impaired vascular response to placentation) before 34 weeks of pregnancy are at an increased...

Randomized Trial Finds Rivaroxaban a Safer Option Than Warfarin for Patients With Atrial Fibrillation...

Sunday, January 15th, 2017
The “triple-therapy” anticoagulation regimen (consisting of a vitamin K antagonist plus dual antiplatelet therapy with a P2Y12 inhibitor and aspirin) has been...
Advertisement

Current Issue

April 2017, Volume 3, Issue 5

This issue examines the art and science of myeloma drug sequencing, Mikkael Sekeres' letter to the ABIM, highlights from the 16th International Myeloma Workshop, and more.